GlyNAC: impressive trials, an unsettled replication question
Glycine + NAC restores glutathione and improved a broad sweep of aging markers in randomized human trials — but those trials are small, single-group, and the one independent attempt missed its primary endpoint.
GlyNAC has one of the most impressive-looking trial records of any longevity supplement — and one of the biggest replication questions. It pairs two cheap amino acids to rebuild glutathione, and the human studies report improvements across almost every hallmark of aging at once. The catch is who ran those studies, and what happened when someone else tried.
What it is
GlyNAC combines glycine and N-acetylcysteine (NAC) — the two amino acids the body needs to make glutathione, its principal intracellular antioxidant. Glutathione levels fall with age, and the GlyNAC hypothesis is simple: supply the building blocks, restore glutathione, and reverse the downstream damage (oxidative stress, mitochondrial decline) that aging glutathione deficiency drives. It’s a more targeted approach than a generic antioxidant pill.
The human trials: broad improvements
The headline evidence is genuinely unusual. In a randomized clinical trial in older adults, 16 weeks of GlyNAC (versus placebo) was reported to improve glutathione levels, oxidative stress, mitochondrial function, inflammation, insulin resistance, gait speed, muscle strength, the 6-minute walk, body composition and blood pressure — a sweep of aging markers few interventions touch at once.[1] An earlier pilot found the same pattern, including cognition, and showed the benefits declined after stopping.[2] A separate pilot in type-2 diabetes put concrete numbers on the metabolic side: two weeks of GlyNAC improved mitochondrial fuel oxidation by 30% and lowered insulin resistance by 22%.[3] Taken at face value, that’s a striking record.
| Evidence | What it shows | Weight it carries |
|---|---|---|
| Sekhar RCT, older adults (n=24) | Broad aging-marker improvement | Real RCT — but small, single-group |
| Sekhar pilot (n=8) | Same pattern incl. cognition | Open-label, tiny |
| Diabetes pilot (n=10) | Mitochondrial fuel +30%, IR −22% | Concrete metabolic numbers, small |
| Independent RCT (n=114) | Missed primary glutathione endpoint | The replication test — negative |
Safety
On safety the picture is consistent and reassuring: glycine and NAC are inexpensive, long-used compounds, and every human GlyNAC trial — including the independent one — reported it was safe and well tolerated.[1][4] So the question with GlyNAC is efficacy and replication, not safety.
The honest bottom line
GlyNAC is one of the more intriguing longevity ideas with actual randomized human data — a coherent mechanism (rebuild glutathione) and trials reporting broad improvements in aging markers.[1] But the evidence is small, comes almost entirely from one group, and the single independent attempt to replicate the core glutathione effect failed its primary endpoint.[4] The fair read is “promising but unreplicated”: a safe, mechanistically sensible supplement worth watching as bigger independent trials run — not a proven anti-aging intervention. For the related cellular-energy pathway with broader (if also modest) data, see NAD+ precursors, and weigh it against other compounds in our longevity evidence matrix.
Reviewed against primary sources by the Aminoscope desk
Sources
- [1] Kumar P, Liu C, Suliburk J, et al. (2023). Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. J Gerontol A Biol Sci Med Sci. PMID 35975308
- [2] Kumar P, Liu C, Hsu JW, et al. (2021). Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial. Clin Transl Med. PMID 33783984
- [3] Kumar P, Osahon OW, Sekhar RV. (2022). GlyNAC Supplementation Improves Impaired Mitochondrial Fuel Oxidation and Lowers Insulin Resistance in Patients with Type 2 Diabetes: Results of a Pilot Study. Antioxidants (Basel). PMID 35052658
- [4] Lizzo G, Migliavacca E, Lametsch R, et al. (2022). A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage. Front Aging. PMID 35821844